Providing leading edge diagnostic solutions in oncology

AccuGenomics provides gene expression tests that accurately diagnose, monitor and inform cancer treatment. AccuGenomics' technologies generate the most comprehensive test results which ensure confidence in clinical decisions and provide credible and reliable gene expression data to the medical community.

Breaking News:

AccuGenomics will give a presentation at the SEQC-2 Workshop September 13-14, 2016, Bethesda, MD

Dr. Willey, AccuGenomics Co-Founder and consultant, has been asked to speak at the SEQC-2 workshop with the presentation title of “Quality‐control solutions for targeted NGS in Cancer Diagnostics.”  “Dr. Willey’s recent publications on standardizing the NGS RNAseq abundance measurements, and DNAseq quality assurance metrics provide needed quality controls for the application of NGS in the…

AccuGenomics presents their molecular standardization technology at GTCbio Molecular Diagnostic Conference in Boston, MA.

Dr. Tom Morrison, CSO of AccuGenomics, gave two presentations at the GTCbio Molecular Diagnostic Conference in Boston, MA July 6-8, 2016.  In his first talk, “Standardized Next Generation Sequencing Abundance Measurements (StarSeq) using Competitive Template Mixtures,” Dr. Morrison describes how the use of AccuGenomics’ competitive mixtures can enable highly multiplex and accurate digital PCR on…

Oxford Global Seminar on NGS Quality Control Solutions

Dr. James Willey, co-founder and consultant to AccuGenomics, is presenting an Oxford Global seminar June 30, 2016.  The talks title is “Quality Control Solutions to Facilitate Implementation of NGS in Cancer Diagnostics.”  The talk will expand upon his recent publications on the use of competitive template mixtures to provide quality metrics for RNASeq and DNASeq…

StarSeq Presented at FDA Workshop on Next Generation Sequencing-Based Oncology Panels

Wilmington, NC February 2016.  Dr. James Willey presents AccuGenomics NGS quality control method at the Public Workshop – Next Generation Sequencing-Based Oncology Panels. The FDA held a public meeting to gather input on strategies for establishing performance characteristics for NGS-based oncology panels for rare variants across tumor types.  This need has become important as more…